Sign In to Follow Application
View All Documents & Correspondence

A Biocatalytic System And Method For Production Of Terminal Alkenes

Abstract: ABSTRACT A BIOCATALYTIC SYSTEM AND METHOD FOR PRODUCTION OF TERMINAL ALKENES The present disclosure relates to a system and method for producing terminal alkenes. The system comprises a fatty acid decarboxylase selected from UndB decarboxylase or a variant 5 thereof; a nicotinamide-cofactor; at least one redox couple for transferring electrons from the nicotinamide cofactor to the fatty acid decarboxylase; and a regeneration system comprising a nicotinamide-cofactor dependent dehydrogenase enzyme, and a substrate. The present disclosure provides a scalable, cost effective, and efficient system and method of producing terminal alkenes by oxidative decarboxylation of fatty acids.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
16 July 2024
Publication Number
31/2024
Publication Type
INA
Invention Field
BIO-CHEMISTRY
Status
Email
Parent Application
Patent Number
Legal Status
Grant Date
2025-08-05
Renewal Date

Applicants

INDIAN INSTITUTE OF SCIENCE
INDIAN INSTITUTE OF SCIENCE, BANGALORE, Karnataka 560012, India

Inventors

1. DAS, Debasis
INDIAN INSTITUTE OF SCIENCE, BANGALORE, Karnataka 560012, India
2. IQBAL, Tabish
INDIAN INSTITUTE OF SCIENCE, BANGALORE, Karnataka 560012, India
3. MURUGAN, Subhashini
INDIAN INSTITUTE OF SCIENCE, BANGALORE, Karnataka 560012, India

Specification

I/We claim:
1. A system comprising:
(a) a fatty acid decarboxylase or a fragment thereof, wherein the fatty acid
decarboxylase is selected from UndB decarboxylase or a variant thereof;
5 (b) a nicotinamide-cofactor;
(c) at least one redox couple for transferring electrons from the
nicotinamide cofactor to the fatty acid decarboxylase; and
(d) a regeneration system comprising a nicotinamide-cofactor dependent
dehydrogenase, and a substrate.
10 2. The system as claimed in claim 1, wherein the fatty acid decarboxylase is UndB
decarboxylase comprising a polypeptide having an amino acid sequence of at least 40%
sequence identity to SEQ ID NO. 1.
3. The system as claimed in any one of claims 1 or 2, wherein said system comprises a
catalase enzyme or fragment thereof, preferably Catalase HPII enzyme or a homologue
15 thereof, proximal to the fatty acid decarboxylase, preferably at a concentration ranging
from 0.1 to 20 µM.
4. The system as claimed in claim 3, wherein said catalase enzyme comprises a
polypeptide having an amino acid sequence of at least 50% sequence identity to SEQ
ID NO. 3.
20 5. The system as claimed in claim 1, wherein said variant is UndB fusion protein
comprising UndB decarboxylase or a fragment thereof, and catalase enzyme or a
fragment thereof, preferably Catalase HPII enzyme or a homologue thereof.
6. The system as claimed in claim 5, wherein said UndB fusion protein comprises a
polypeptide having an amino acid sequence of at least 60% sequence identity to SEQ
25 ID NO. 2.
7. The system as claimed in claim 1, wherein the nicotinamide cofactor is selected from
nicotinamide adenine dinucleotide (NADH), nicotinamide adenine dinucleotide
phosphate (NADPH), phenylethyl nicotinamide (P2NAH), thionicotinamide adenine
dinucleotide (thio-NADH), 3-acetylpyridine adenine dinucleotide (APADH), N30 methyl-1,4-dihydronicotinamide (MNAH) and N-benzyl-1,4-dihydronicotinamide
(BNAH), or an analogue thereof.
8. The system as claimed in claim 1, wherein concentration of the nicotinamide cofactor
ranges from 50 µM to 2000 µM, preferably 100 µM to 200 µM.
34
9. The system as claimed in claim 1, wherein the dehydrogenase enzyme is selected from
glucose dehydrogenase, glutamate dehydrogenase, mannitol dehydrogenase, phosphite
dehydrogenase, formate dehydrogenase, or combination thereof; and wherein the
substrate is selected from glucose, galactose, xylose, fructose, glutamate, mannitol,
5 phosphite, formate, or combination thereof.
10. The system as claimed in claim 1, wherein the redox couple is selected from ferredoxin
and ferredoxin reductase; putidaredoxin and putidaredoxin reductase; cytochrome b5
and cytochrome b5 reductase; or combination thereof, preferably ferredoxin and
ferredoxin reductase.

Documents

Orders

Section Controller Decision Date
u/s 15,43 sudha javeria 2025-08-05
u/s 15,43 sudha javeria 2025-08-05

Application Documents

# Name Date
1 202441054447-STATEMENT OF UNDERTAKING (FORM 3) [16-07-2024(online)].pdf 2024-07-16
2 202441054447-Sequence Listing in XML (WIPO ST26) [16-07-2024(online)].pdf 2024-07-16
3 202441054447-Sequence Listing in PDF [16-07-2024(online)].pdf 2024-07-16
4 202441054447-REQUEST FOR EARLY PUBLICATION(FORM-9) [16-07-2024(online)].pdf 2024-07-16
5 202441054447-POWER OF AUTHORITY [16-07-2024(online)].pdf 2024-07-16
6 202441054447-FORM-9 [16-07-2024(online)].pdf 2024-07-16
7 202441054447-FORM FOR SMALL ENTITY(FORM-28) [16-07-2024(online)].pdf 2024-07-16
8 202441054447-FORM 1 [16-07-2024(online)].pdf 2024-07-16
9 202441054447-EVIDENCE FOR REGISTRATION UNDER SSI(FORM-28) [16-07-2024(online)].pdf 2024-07-16
10 202441054447-EDUCATIONAL INSTITUTION(S) [16-07-2024(online)].pdf 2024-07-16
11 202441054447-DRAWINGS [16-07-2024(online)].pdf 2024-07-16
12 202441054447-DECLARATION OF INVENTORSHIP (FORM 5) [16-07-2024(online)].pdf 2024-07-16
13 202441054447-COMPLETE SPECIFICATION [16-07-2024(online)].pdf 2024-07-16
14 202441054447-FORM-8 [18-07-2024(online)].pdf 2024-07-18
15 202441054447-FORM 18A [18-07-2024(online)].pdf 2024-07-18
16 202441054447-EVIDENCE OF ELIGIBILTY RULE 24C1f [18-07-2024(online)].pdf 2024-07-18
17 202441054447-Proof of Right [26-07-2024(online)].pdf 2024-07-26
18 202441054447-FER.pdf 2024-08-27
19 202441054447-FORM 3 [20-09-2024(online)].pdf 2024-09-20
20 202441054447-OTHERS [25-09-2024(online)].pdf 2024-09-25
21 202441054447-MARKED COPIES OF AMENDEMENTS [25-09-2024(online)].pdf 2024-09-25
22 202441054447-FORM 13 [25-09-2024(online)].pdf 2024-09-25
23 202441054447-FER_SER_REPLY [25-09-2024(online)].pdf 2024-09-25
24 202441054447-COMPLETE SPECIFICATION [25-09-2024(online)].pdf 2024-09-25
25 202441054447-CLAIMS [25-09-2024(online)].pdf 2024-09-25
26 202441054447-AMMENDED DOCUMENTS [25-09-2024(online)].pdf 2024-09-25
27 202441054447-US(14)-HearingNotice-(HearingDate-10-07-2025).pdf 2025-06-11
28 202441054447-FORM-26 [01-07-2025(online)].pdf 2025-07-01
29 202441054447-Correspondence to notify the Controller [03-07-2025(online)].pdf 2025-07-03
30 202441054447-Written submissions and relevant documents [24-07-2025(online)].pdf 2025-07-24
31 202441054447-Annexure [24-07-2025(online)].pdf 2025-07-24
32 202441054447-Response to office action [28-07-2025(online)].pdf 2025-07-28
34 202441054447-PatentCertificate05-08-2025.pdf 2025-08-05
35 202441054447-IntimationOfGrant05-08-2025.pdf 2025-08-05

Search Strategy

1 202441054447E_18-08-2024.pdf

ERegister / Renewals

3rd: 13 Aug 2025

From 16/07/2026 - To 16/07/2027

4th: 13 Aug 2025

From 16/07/2027 - To 16/07/2028

5th: 13 Aug 2025

From 16/07/2028 - To 16/07/2029

6th: 13 Aug 2025

From 16/07/2029 - To 16/07/2030

7th: 13 Aug 2025

From 16/07/2030 - To 16/07/2031

8th: 13 Aug 2025

From 16/07/2031 - To 16/07/2032

9th: 13 Aug 2025

From 16/07/2032 - To 16/07/2033

10th: 13 Aug 2025

From 16/07/2033 - To 16/07/2034